Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Abstract PO1-18-04: Neoadjuvant pembrolizumab + decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2- breast cancer (NCT02957968)

Cancer Res (2024) 84 (9_Supplement): PO1-18-04.

https://doi.org/10.1158/1538-7445.SABCS23-PO1-18-04

Published: 02 May 2024

View article titled, Abstract PO1-18-04: Neoadjuvant pembrolizumab + decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2- breast cancer (NCT02957968)

Journal Articles

Abstract OT1-01-02: Neoadjuvant pembrolizumab + decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2-breast cancer

Harry Douglas Bear, Michael O. Idowu, Andrew Poklepovic, Adam Sima, Maciej Kmieciak

Cancer Res (2020) 80 (4_Supplement): OT1-01-02.

https://doi.org/10.1158/1538-7445.SABCS19-OT1-01-02

Published: 15 February 2020

View article titled, Abstract OT1-01-02: Neoadjuvant pembrolizumab + decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2-breast cancer

Journal Articles

Abstract LB-081: Co-targeting BCL-2 and PI3K potently induces BAXdependent mitochondrial apoptosis in AML

Steven Grant, Mohamed Rahmani, Jewel Nkwocha, Maciej Kmieciak, Joel Leverson, Deepak Sampath

Cancer Res (2018) 78 (13_Supplement): LB-081.

https://doi.org/10.1158/1538-7445.AM2018-LB-081

Published: 01 July 2018

View article titled, Abstract LB-081: Co-targeting BCL-2 and PI3K potently induces BAXdependent mitochondrial apoptosis in AML

Journal Articles

Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells

Mohamed Rahmani, Jewel Nkwocha, Elisa Hawkins, Xinyan Pei, Rebecca E. Parker, Maciej Kmieciak, Joel D. Leverson, Deepak Sampath, Andrea Ferreira-Gonzalez, Steven Grant

Cancer Res (2018) 78 (11): 3075–3086.

https://doi.org/10.1158/0008-5472.CAN-17-3024

Published: 31 May 2018

View article titled, Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells

Includes: Supplementary data

Journal Articles

Abstract 2018: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin’s lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms

Tri Nguyen, Rebecca Parker, Elisa Hawkins, Victor Yazbeck, Akhil Kolluri, Maciej Kmieciak, Mohamed Rahmani, Steven Grant

Cancer Res (2017) 77 (13_Supplement): 2018.

https://doi.org/10.1158/1538-7445.AM2017-2018

Published: 01 July 2017

View article titled, Abstract 2018: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin’s lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms

Journal Articles

Abstract 3020: Targeting both canonical and non-canonical NF-kB pathways by the IAP antagonist birinapant potentiates bortezomib anti-myeloma activity

Liang Zhou, Shuang Chen, Yu Zhang, Maciej Kmieciak, Yun Leng, Lihong Li, Hui Lin, Joel Turner, Daniel Sullivan, Yun Dai, Steven Grant

Cancer Res (2016) 76 (14_Supplement): 3020.

https://doi.org/10.1158/1538-7445.AM2016-3020

Published: 15 July 2016

View article titled, Abstract 3020: Targeting both canonical and non-canonical NF-kB pathways by the IAP antagonist birinapant potentiates bortezomib anti-myeloma activity

Journal Articles

Abstract LB-258: The NAE inhibitor pevonedistat (MLN4924) interacts with the HDAC inhibitor belinostat via disruption of the intra-S checkpoint and both HR and NHEJ DNA repair in AML cells

Liang Zhou, Shuang Chen, Yu Zhang, Yun Leng, Lihong Li, Hui Lin, Maciej Kmieciak, Kathryn A. Rizzo, Catherine I. Dumur, Andrea Ferreira-Gonzalez, Yun Dai, Steven Grant

Cancer Res (2015) 75 (15_Supplement): LB-258.

https://doi.org/10.1158/1538-7445.AM2015-LB-258

Published: 01 August 2015

View article titled, Abstract LB-258: The NAE inhibitor pevonedistat (MLN4924) interacts with the HDAC inhibitor belinostat via disruption of the intra-S checkpoint and both HR and NHEJ DNA repair in AML cells

Journal Articles

Abstract 4556: A therapeutic strategy combining the Wee1 inhibitor MK1775 with HDAC inhibitors targets both p53 wild-type or mutant AML cells

Yu Zhang, Liang Zhou, Shuang Chen, Maciej Kmieciak, Hui Lin, Yun Dai, Steven Grant

Cancer Res (2014) 74 (19_Supplement): 4556.

https://doi.org/10.1158/1538-7445.AM2014-4556

Published: 01 October 2014

View article titled, Abstract 4556: A therapeutic strategy combining the Wee1 inhibitor MK1775 with HDAC inhibitors targets both p53 wild-type or mutant AML cells

Journal Articles

Abstract 3420: The novel Chk1 inhibitor MK8776 sensitizes AML cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.

Shuang Chen, Maciej Kmieciak, Liang Zhou, Hui Lin, Xin-Yan Pei, Yun Dai, Steven Grant

Cancer Res (2013) 73 (8_Supplement): 3420.

https://doi.org/10.1158/1538-7445.AM2013-3420

Published: 15 April 2013

View article titled, Abstract 3420: The novel Chk1 inhibitor MK8776 sensitizes AML cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.

Journal Articles

Abstract 775: Sequential common gamma-chain cytokines facilitate differentiation of tumor-reactive T cells that are resistant to MDSC and can induce rejection of breast tumors

Kyle K. Payne, Maciej Kmieciak, Debasmita Basu, Viswanathan Ramakrishnan, Harry D. Bear, Masoud H. Manjili

Cancer Res (2011) 71 (8_Supplement): 775.

https://doi.org/10.1158/1538-7445.AM2011-775

Published: 15 April 2011

View article titled, Abstract 775: Sequential common gamma-chain cytokines facilitate differentiation of tumor-reactive T cells that are resistant to MDSC and can induce rejection of breast tumors

Journal Articles

Myeloid-derived suppressor cells are key inhibitors of adoptive immunotherapy targeting HER-2/neu positive breast carcinomas

Johanna Morales, Maciej Kmieciak, Harry Bear, Masoud Manjili

Cancer Res (2008) 68 (9_Supplement): 246.

Published: 01 May 2008

View article titled, Myeloid-derived suppressor cells are key inhibitors of adoptive immunotherapy targeting HER-2/neu positive breast carcinomas

Journal Articles

Signatures Associated with Rejection or Recurrence in HER-2/neu–Positive Mammary Tumors

Andrea Worschech, Maciej Kmieciak, Keith L. Knutson, Harry D. Bear, Aladar A. Szalay, Ena Wang, Francesco M. Marincola, Masoud H. Manjili

Cancer Res (2008) 68 (7): 2436–2446.

https://doi.org/10.1158/0008-5472.CAN-07-6822

Published: 01 April 2008

View article titled, Signatures Associated with Rejection or Recurrence in HER-2/neu–Positive Mammary Tumors

Includes: Supplementary data

Journal Articles

HER-2/neu antigen loss and relapse of mouse mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses: role of IFN- γ

Masoud Manjili, Maciej Kmieciak, Catherine Dumur, Keith Knutson

Cancer Res (2007) 67 (9_Supplement): 215.

Published: 01 May 2007

View article titled, HER-2/neu antigen loss and relapse of mouse mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses: role of IFN- γ

Journal Articles

Anti-tumor immune responses facilitate tumor escape in HER-2/neu positive primary mammary tumors and emergence of the relapse phenotype

Maciej Kmieciak, Masoud H. Manjili

Cancer Res (2006) 66 (8_Supplement): 529.

Published: 15 April 2006

View article titled, Anti-tumor immune responses facilitate tumor escape in HER-2/neu positive primary mammary tumors and emergence of the relapse phenotype

NARROW

Abstract PO1-18-04: Neoadjuvant pembrolizumab + decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2- breast cancer (NCT02957968)

Abstract OT1-01-02: Neoadjuvant pembrolizumab + decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2-breast cancer

Abstract LB-081: Co-targeting BCL-2 and PI3K potently induces BAXdependent mitochondrial apoptosis in AML

Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells

Abstract 2018: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin’s lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms

Abstract 3020: Targeting both canonical and non-canonical NF-kB pathways by the IAP antagonist birinapant potentiates bortezomib anti-myeloma activity

Abstract LB-258: The NAE inhibitor pevonedistat (MLN4924) interacts with the HDAC inhibitor belinostat via disruption of the intra-S checkpoint and both HR and NHEJ DNA repair in AML cells

Abstract 4556: A therapeutic strategy combining the Wee1 inhibitor MK1775 with HDAC inhibitors targets both p53 wild-type or mutant AML cells

Abstract 3420: The novel Chk1 inhibitor MK8776 sensitizes AML cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.

Abstract 775: Sequential common gamma-chain cytokines facilitate differentiation of tumor-reactive T cells that are resistant to MDSC and can induce rejection of breast tumors

Myeloid-derived suppressor cells are key inhibitors of adoptive immunotherapy targeting HER-2/neu positive breast carcinomas

Signatures Associated with Rejection or Recurrence in HER-2/neu–Positive Mammary Tumors

HER-2/neu antigen loss and relapse of mouse mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses: role of IFN- γ

Anti-tumor immune responses facilitate tumor escape in HER-2/neu positive primary mammary tumors and emergence of the relapse phenotype

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only